Alteplase: Nursing Drug Guide, Bleeding Risk & NCLEX Review

Alteplase is a recombinant tissue plasminogen activator supplied for intravenous reconstitution. Verify the vial strength, diluent, and pharmacy-prepared infusion bag on the MAR before every dose.

The primary U.S. brand is Activase (Genentech), available as 50 mg and 100 mg lyophilized powder vials with Sterile Water for Injection for reconstitution. Generic alteplase may appear on formularies under the international nonproprietary name. Do not confuse Activase with other fibrinolytics or anticoagulants on crash carts or stroke code trays.

Activase is a tissue plasminogen activator (tPA) indicated for selected thrombotic emergencies when benefit outweighs bleeding risk. Nursing workflow differs by indication—AIS requires non-contrast head imaging and strict blood pressure control; AMI and PE regimens integrate anticoagulant and antiplatelet therapy per protocol.

↔On a small screen, swipe or scroll sideways to see the full table.

Alteplase is a serine protease that binds fibrin in a thrombus and converts entrapped plasminogen to plasmin, initiating local fibrinolysis with limited systemic proteolysis when fibrin is present. When introduced at pharmacologic concentrations, some systemic fibrinogen degradation can occur—nurses should expect coagulation studies may be unreliable during therapy unless specific sampling precautions are taken per labeling.

Because thrombolysis can expose underlying venous thrombus, consider re-embolization risk in massive PE—Activase has not been shown to treat underlying deep vein thrombosis adequately, and lysis of DVT may contribute to recurrent emboli per labeling.

All Activase doses are weight-based or capped by maximum totals. Independent double-check of mg, mL, bolus percentage, and infusion duration is mandatory—dose-finding data in AIS suggested doses above 0.9 mg/kg may increase intracranial hemorrhage risk.

Missed dose: Not specified in the reviewed prescribing information. Activase is a time-critical single-course infusion—if infusion is interrupted for bleeding or protocol hold, notify prescriber and pharmacy immediately; do not restart without explicit order.

Pretreatment checks

• Confirm indication, weight, and time from symptom onset (AIS within 3 hours; AMI/PE per local protocol windows)
• Review non-contrast head CT scan for AIS—exclude intracranial hemorrhage before bolus
• Verify coagulation status: discontinue Activase if pretreatment INR is >1.7 or aPTT is elevated for AIS; review anticoagulant and antiplatelet use through medication reconciliation
• Assess blood pressure and bleeding risk factors (recent surgery, trauma, GI/GU bleeding, severe hypertension)
• Confirm facility capability for neuroimaging and hemorrhage management for AIS per labeling

Contraindications

Acute ischemic stroke — do not administer when bleeding risk exceeds benefit:

• Current intracranial hemorrhage or subarachnoid hemorrhage
• Active internal bleeding
• Recent (within 3 months) intracranial or intraspinal surgery or serious head trauma
• Intracranial conditions that may increase bleeding risk (e.g., some neoplasms, AVMs, aneurysms)
• Bleeding diathesis
• Current severe uncontrolled hypertension

Acute MI or PE — additionally includes history of recent stroke among labeled contraindications, plus active internal bleeding, recent intracranial/intraspinal surgery or serious head trauma, intracranial bleeding-risk conditions, bleeding diathesis, and current severe uncontrolled hypertension.

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Intravenous only. Do not add other medications to infusion solutions containing Activase. Use within 8 hours after reconstitution when stored at 2–30°C.

• Reconstitute with supplied Sterile Water for Injection only—not bacteriostatic water. May administer at 1 mg/mL or dilute to 0.5 mg/mL in 0.9% sodium chloride or 5% dextrose per labeling
• AIS: administer 10% of total dose as IV bolus over 1 minute, then infuse remainder over 60 minutes via pump with independent double-check
• PE: 100 mg over 2 hours; AMI: accelerated or 3-hour weight-based regimens per order—never exceed 100 mg total for AMI
• Avoid intramuscular injections, minimize arterial and venous punctures, and avoid internal jugular/subclavian lines when possible during infusion
• Follow high-alert medication administration protocols: dedicated line when feasible, two-nurse verification, and programmed pump guardrails
• If extravasation occurs, stop infusion at that site and apply local therapy per protocol

• AIS: improving neurological examination over hours to days—NIH Stroke Scale or facility stroke scale trending favorably; absence of sudden decline suggesting hemorrhagic conversion
• AMI: resolution or reduction of chest pain, improving hemodynamics, and reperfusion markers per protocol—not specified as single nursing endpoint in labeling
• PE: improved oxygenation, hemodynamic stability, and reduced right-heart strain signs when lysis succeeds
• Ongoing fibrinogen decrease may occur; coagulation tests during therapy may not reflect true in-vivo status per labeling

Bleeding is the most frequent adverse reaction. Hemorrhage can occur during infusion or days later while anticoagulation continues. Stop the infusion and escalate immediately.

• Sudden neurological worsening, severe headache, vomiting, or declining level of consciousness after AIS thrombolysis—suspect symptomatic intracranial hemorrhage; obtain urgent imaging
• New focal weakness, aphasia, or vision change after initial improvement
• Altered mental status, seizure, or signs of cerebral edema/herniation (post-marketing reports)
• Active bleeding at IV, arterial, or surgical sites; hemodynamic instability; falling hemoglobin or hematocrit
• Hypotension, angioedema, urticaria, or anaphylactoid reaction during infusion—discontinue Activase and treat per hypersensitivity protocol
• Gastrointestinal or genitourinary bleeding, retroperitoneal hemorrhage, or any bleeding that is difficult to control because of location

↔On a small screen, swipe or scroll sideways to see the full table.

Overdose manifests primarily as bleeding complications. AIS dose-finding suggested doses greater than 0.9 mg/kg may increase intracranial hemorrhage risk. AMI doses above 100 mg (e.g., 150 mg regimens) have been associated with increased intracranial bleeding per labeling.

Management

• Discontinue Activase infusion immediately if serious bleeding occurs
• Apply local pressure to compressible sites; reverse anticoagulation per protocol when heparin or warfarin contributed
• Not specified in the reviewed prescribing information as a routine antidote. Cryoprecipitate, antifibrinolytics, or surgical intervention may be considered by the treating team for life-threatening bleeding per institutional protocol

• Alteplase vs tenecteplase (TNK) vs reteplase—different fibrinolytics with different doses and reconstitution; verify drug name and indication on stroke or code cart
• Activase vs other “ase” thrombolytics—confirm vial strength (50 mg vs 100 mg) and total calculated dose before bolus
• mg vs mL—reconstituted concentration is 1 mg/mL (or 0.5 mg/mL if further diluted); bolus is 10% of total mg, not 10% of bag volume without calculation
• Alteplase vs anticoagulants on the MAR— thrombolytic bolus must not be confused with heparin bolus or antiplatelet loading doses on code sheets
• Duplicate thrombolytic orders—second fibrinolytic course is not standard; clarify if repeat imaging shows new indication

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Neurological status with formal neurological assessment at protocol intervals after AIS—any sudden change triggers imaging pathway
• Blood pressure before, during, and for 24 hours after AIS thrombolysis using standardized blood pressure measurement technique
• All puncture sites, gums, urine, stool, and drain output for occult or overt bleeding during and for at least 24 hours
• Vital signs, oxygenation, and cardiac rhythm during AMI/PE infusions
• Hypersensitivity signs (rash, angioedema, bronchospasm) during and several hours after infusion

Document

• Indication, patient weight, total mg ordered, bolus mg and mL, infusion start/stop times, and independent double-check initials
• Time of symptom onset, CT result excluding hemorrhage (AIS), pretreatment INR/aPTT/PT when available, and blood pressure before bolus
• Neurological assessments with timestamps; any hold, interruption, or adverse event with prescriber notification
• Patient/family teaching on bleeding precautions and when to call the team

• This medication dissolves clots but increases bleeding risk—you may bruise easily or bleed longer from minor cuts
• Report immediately: sudden severe headache, vomiting, confusion, vision change, weakness, or blood in urine/stool
• Minimize needle sticks and avoid IM injections while on thrombolytic therapy per care team instructions
• Do not take additional aspirin, ibuprofen, or blood thinners unless specifically ordered after thrombolysis window
• Bed rest and blood pressure control may be required for 24 hours after stroke thrombolysis—follow nurse instructions about activity and toileting assistance

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional stroke, MI, or PE protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

This NCLEX-style clinical judgment practice set for alteplase uses a tabbed acute ischemic stroke case (MAR, labs, vitals, nursing notes) with a mandatory matrix urgency item—then rotates priority action after case-tab review, bleeding-risk cue recognition, post-thrombolysis trend interpretation, AIS bolus sequencing, INR hold judgment, and matrix sorting of expected versus urgent findings (recognise cues → analyse → prioritise → act → evaluate outcomes).

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.